RAS testing in metastatic colorectal cancer: advances in Europe by Krieken, J.H.J.M. van et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/171322
 
 
 
Please be advised that this information was generated on 2018-07-07 and may be subject to
change.
REVIEWAND PERSPECTIVES
RAS testing in metastatic colorectal cancer: advances in Europe
J Han JM Van Krieken1 & Etienne Rouleau2 & Marjolijn J. L. Ligtenberg1 &
Nicola Normanno3 & Scott D. Patterson4,7 & Andreas Jung5,6
Received: 4 June 2015 /Revised: 20 October 2015 /Accepted: 22 October 2015 /Published online: 16 November 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Personalized medicine shows promise for maximiz-
ing efficacy and minimizing toxicity of anti-cancer treatment.
KRAS exon 2 mutations are predictive of resistance to epider-
mal growth factor receptor-directed monoclonal antibodies in
patients with metastatic colorectal cancer. Recent studies have
shown that broader RAS testing (KRAS and NRAS) is needed to
select patients for treatment. While Sanger sequencing is still
used, approaches based on variousmethodologies are available.
Few CE-approved kits, however, detect the full spectrum of
RAS mutations. More recently, “next-generation” sequencing
has been developed for research use, including parallel semi-
conductor sequencing and reversible termination. These tech-
niques have high technical sensitivities for detecting mutations,
although the ideal threshold is currently unknown. Finally, liq-
uid biopsy has the potential to become an additional tool to
assess tumor-derived DNA. For accurate and timely RAS test-
ing, appropriate sampling and prompt delivery of material is
critical. Processes to ensure efficient turnaround from sample
request to RAS evaluation must be implemented so that patients
receive the most appropriate treatment. Given the variety of
methodologies, external quality assurance programs are impor-
tant to ensure a high standard of RAS testing. Here, we review
technical and practical aspects of RAS testing for pathologists
working with metastatic colorectal cancer tumor samples. The
extension of markers from KRAS to RAS testing is the new
paradigm for biomarker testing in colorectal cancer.
Keywords Colorectal cancer . RAS . Biomarkers .
Sequencing . Quality assurance programs
Introduction
Personalized medicine and tailoring of therapy to individual pa-
tients is a promising approach for maximizing efficacy and min-
imizing the toxicity of anti-cancer treatment [1]. Furthermore,
such an approach can generate healthcare cost savings, as treat-
ments are given only to patients likely to benefit [2]. In recent
years, a few molecular tumor biomarkers—characteristics “that
can be objectively measured and evaluated as an indicator of
pathogenic processes or treatment response” [3]—have been
identified, enabling anti-cancer treatments to be better tailored
to individual patients’ tumors [1]. Those molecular biomarkers
have provided alternative therapeutic options and improved pa-
tient outcomes, especially in metastatic colorectal cancer
(mCRC). In the European Union, there were an estimated 342,
000 new cases of colorectal cancer in 2012 (46.3 per 100,000
individuals), and mCRC remains the second leading cause of
cancer-related deaths (215,000 deaths in 2012) [4].
Epidermal growth factor receptor (EGFR)-targeted mono-
clonal antibodies (mAbs) have been investigated for the treat-
ment of mCRC, but the benefits to patients were small in
initial clinical trials when these agents were unselectively
added to standard care. Subsequently, KRAS mutations,
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particularly those in exon 2 (detectable in about 30–40 % of
patients with mCRC) [5, 6] were identified as a predictive
biomarker of resistance to the EGFR-targeted antibodies.
These mutations result in constitutive activation of the
GTPase KRAS, leading to activation of signaling downstream
of the EGFR [7–10]. Consequently, in patients with exon 2
wild-type (WT) KRAS tumors, addition of EGFR inhibitory
antibodies to standard chemotherapy significantly improved
progression-free survival (PFS) versus chemotherapy alone
[8, 11]. For example, in the phase III, first-line PRIME study,
oxaliplatin, 5-fluorouracil (5-FU), and leucovorin
(FOLFOX4) plus panitumumab was associated with a median
PFS of 9.6 versus 8.0 months for FOLFOX4 alone (p = 0.02),
while median overall survival [OS] was 23.9 and 19.7months,
respectively (p = 0.072) [8]. Similarly, median PFS with
irinotecan, 5-FU, and leucovorin (FOLFIRI) plus cetuximab
in the CRYSTAL study was 9.9 versus 8.4 months with
FOLFIRI alone (p = 0.0012) and OS was 23.5 versus
20.0 months (p = 0.0093), respectively [11]. In patients with
mutantKRAS tumors, combination of anti-EGFR therapy with
irinotecan-based chemotherapy is associated with little or no
benefit [9, 12, 13], while combination of anti-EGFR therapy
with oxaliplatin-based chemotherapy in such patients may be
detrimental to both PFS and OS [8, 14, 15].
While KRAS exon 2 mutations are undoubtedly useful for
predicting a lack of activity of EGFR-targeted mAbs, use of
this biomarker increased response rates only from ~15% in an
unselected population to ~30 % in patients with KRAS exon 2
WTmCRC [16]. Analyses of tumor samples from the PRIME
study in mCRC have shown that more comprehensive RAS
testing (i.e., exon 2, 3, and 4 of both KRAS and NRAS) better
selects those patients more likely to respond to EGFR inhibi-
tors, with RAS WT populations experiencing a statistically
significant improvement in OS versus chemotherapy alone
(26 versus 20.2 months; p = 0.04) [14]. Furthermore, data
from the phase II PEAK and phase III FIRE-3 studies indicat-
ed that patients with WT RAS tumors experienced greater
benefit from mFOLFOX6 plus panitumumab (PEAK) or
FOLFIRI plus cetuximab (FIRE-3) than from mFOLFOX6
or FOLFIRI, respectively, plus bevacizumab in terms of PFS
in PEAK only (PEAK, 13.0 versus 9.5 months; p = 0.029 and
FIRE-3, 10.0 versus 10.3 months; p = 0.55) and OS in both
(PEAK, 34.2 versus 24.3 months; p = 0.009 and FIRE-3, 28.7
versus 25.0 months; p = 0.017) [17, 18]. Taken together, mu-
tations in either KRAS or the closely related NRAS gene, but
not in theBRAF gene, were found to be associatedwith lack of
response to EGFR-targeted mAbs [18–24].
In several large studies including patients withmCRC, over
half of patients were found to have tumors harboring muta-
tions in KRAS or NRAS (Table 1) [10, 14, 18, 19, 25–31]. For
example, 17 % of patients with tumors WT for KRAS codons
12 and 13 in the PRIME study (~10 % of patients overall)
were found to have mutations in other KRAS codons and/or
NRAS [14]. A pooled analysis of five studies (n = 2832 pa-
tients with KRAS and NRAS data available) showed that the
prevalence of RAS mutations was 55.9 % (95 % confidence
interval [CI], 53.9–57.9 %) [32]. More recently, a meta-
analysis of nine randomized controlled trials (n = 5948)
showed that EGFR-targeted mAb therapy in a RAS WT pop-
ulation had a significantly superior PFS (p < 0.001) and OS
(p = 0.008) treatment effect compared with in a RAS mutant
population [33].
As patients with mutant RAS tumors do not benefit from
EGFR inhibitors, and may even experience worse outcomes
when EGFR inhibitors are combined with oxaliplatin-based
chemotherapy [14, 15], the European Public Assessment
Report summaries of product characteristics (SmPCs) for
panitumumab and cetuximab specify that “evidence of wild-
type RAS (KRAS andNRAS) status is required before initiating
treatment” [34, 35]. RAS gene testing has therefore become an
important part of the work-up of patients with mCRC in
Europe. Thus, it is essential that genetic testing is conducted
to a high standard and as quickly as possible in case a patient is
eligible for EGFR-targeted treatment. The highest quality of
testing is achieved when the genetic analysis is carried out in
the context of a histopathological evaluation [36, 37] to ensure
that appropriate tissue areas are included in the analysis. To
test and ensure the quality of RAS testing (i.e., the correct
identification ofWT [specificity] and mutant RAS [sensitivity]
to eliminate false-positive and false-negative results), external
quality assurance (EQA) programs play a critical role. This
view is supported by the European Medicines Agency
(EMA), as the SmPCs for panitumumab and cetuximab state
that “mutational status should be determined by an experi-
enced laboratory using validated test methods for detection
of KRAS and NRAS (exons 2, 3, and 4) mutations” [34, 35].
As “experience” is only vaguely definable, a test by an EQA
program is a suitably objective tool to verify a laboratory’s
experience as noted in the SmPC for panitumumab: “if
[panitumumab] is to be used in combination with FOLFOX
then it is recommended that mutational status be determined
by a laboratory that participates in aRAS EQA program orWT
status be confirmed in a duplicate test” [34].
Full tumor RAS testing—rather than solely KRAS exon 2
testing—is included in treatment guidelines for mCRC such as
those from the European Society for Medical Oncology
(ESMO), the National Comprehensive Cancer Network
(NCCN), the German Cancer Society Association of
Medical Oncology (AIO), and the Dutch Landelijke
Werkgroep Gastro Intestinale Tumoren [38–41].
The shift from screening a single KRAS locus to multiple
RAS loci highlights the evolution of biomarker testing to de-
tect multiple mutation sites. This change in approach may
affect the choice of screening methods used, as many different
techniques for assessing RAS mutation status are now avail-
able [42]. The aim of this review is to describe these different
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methods, focusing on those most commonly used in Europe:
sequencing (Sanger sequencing, pyrosequencing, next-
generation sequencing [NGS] techniques), other in vitro diag-
nostic techniques, and laboratory-developed techniques.
These approaches differ in both their limit of detection
(LOD; sensitivity) and their specificity. Some of the key issues
in RAS testing will be discussed, including sensitivity of test-
ing and EQA programs.
Initial material—DNA from formalin-fixed,
paraffin-embedded tissue blocks
To assess RAS mutation status, analysis is usually performed
on DNA extracted from formalin-fixed, paraffin-embedded
(FFPE) tissue blocks [43]. As a result of chemical modifica-
tion and DNA fragmentation, the amplicon size in polymerase
chain reactions (PCR) is limited to about 150 base pairs, when
sequencing is performed on FFPE-derived DNA [44].
Moreover, for NGS, the initial procedure for DNA isolation
from FFPE tissue blocks remains the same as for conventional
DNA sequencing [43] and is, therefore, subject to some of the
same issues of DNA quantity and quality.
DNA sequencing methods
Most sequencing methods can screen a gene locus for muta-
tions. Newer sequencing methods provide quantitative
information and increase the number of loci that can be ana-
lyzed in parallel.
Sanger sequencing (also known as “terminated chain se-
quencing” or “dideoxy sequencing”) is considered to be a
standard method for analyzing DNA sequences and thus also
for RAS testing [43, 44]. Overall, it is the most widely used
method of RAS testing in Europe [45], although its use varies
from country to country. Major improvements to the original
Sanger technique have resulted in reduced reagent volumes
and consumable costs, as well as increased throughput [46],
although it is still considered time consuming compared with
some other methods [44]. The advantage of this method is its
ability to detect all types of mutation (single-nucleotide
substitutions, insertions, and deletions) in the amplified locus.
If DNA is isolated from FFPE tissue, the size of the amplicons
to be analyzed should not exceed 150 base pairs. To ensure
reproducibility, bidirectional sequencing reactions are per-
formed using forward and reverse primers [47]. Each run
gives the nucleotide sequence of one amplified locus; up to
96 runs can be performed in parallel (usually 16 to 24). In
addition, the LOD for Sanger sequencing is relatively modest
compared with other techniques. Multiple studies have shown
that Sanger sequencing requires at least 10–25 % of the neo-
plastic cells in the sample to contain KRAS mutations for reli-
able detection [48]. Several enrichment methods are available,
however, to increase the concentration of mutant DNA, thus
improving the overall sensitivity of the detection process
Table 1 Prevalence of RAS mutations in patients with metastatic colorectal carcinoma
Study Detection method RAS mutation prevalence
KRAS NRAS Total
Exon 2 Exon 3 Exon 4 Exon 2 Exon 3 Exon 4
PRIME [14] TheraScreen 40 % 4 %a 6 % 3 % 4 %a 0 % 52 %a
20050408 [19] DxS/Qiagen/NGS/Sanger 42 % 2 %a NS 5 %a NS NS
20050408 (updated) [26] NGS/Sanger + WAVE/SURVEYOR® 43 % 5 %a 5 % 4 % 3 %a 1 % NS
20050181 [25] DxS/Qiagen/NGS/Sanger 45 % 4 % 8 % 2 % 6 % 0 % 58 %
PICCOLO [27] Pyrosequencing NAb NAb 4 %c 6 %a NS NS
PEAK [18] Therascreen + WAVE/SURVEYOR® NAd 4 % 7 % 5 % 6 % 0 % NS
CRYSTAL [10] LightMix 36 % NS NS NS NS NS NS
CRYSTAL (updated) [28] BEAMing 37 % 3 % 5 % 4 % 3 % 2 % 43 %
COIN [29] Pyrosequencing 43 %a NS 4 %a,e NS NS
FIRE-3 [30] Pyrosequencing NAd 4 % 5 % 4 % 2 % 0 % NS
OPUS [31] BEAMing NAd 6 % 9 % 7 % 5 % 1 % NS
BEAM beads, emulsions, amplification, and magnetics, NGS next-generation sequencing, NS not specified, PCR polymerase chain reaction
a Not including codon 59
b Study population limited to patients with KRAS (exon 2 and exon 3 codon 61) wild-type tumors
c Not including codon 117
d Study population limited to patients with KRAS (exon 2) wild-type tumors
e Not including codon 13
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(Table 2) [49–53]. Another limitation of Sanger sequencing is
the low level of precision in the variant fraction (i.e., the per-
centage of tested alleles that are mutant); the error rate (i.e., the
percentage of incorrectly identified bases) of the Sanger se-
quencing reaction is estimated at 0.001 to >1%, depending on
the software that is used post processing [54].
Pyrosequencing is an alternative method to Sanger se-
quencing that can provide both quantitative information
and a low technical LOD (5–10 %) [55], although the
sequencing error rate may be higher (4–25 %) [56].
During pyrosequencing, the incorporation of each nucle-
otide is followed in real time by the emission of a specific
light unit based on the amount of pyrophosphate, which is
released in stoichiometric amounts during the elongation
reaction and converted by an enzymatic cascade into
adenosine triphosphate (ATP) molecules each time a nu-
cleotide is incorporated. The ATP serves as the energy
donor in a bioluminescence reaction resulting in emission
of light that can be measured as a peak in the pyrogram
output. Pyrosequencing allows the local separation of mu-
tant and WT signals, although the presence of homopoly-
mers can limit the method, as linearity is present only for
some nucleotides. In this approach, each run gives the
nucleotide sequence of one amplified locus, but the size
of the sequence (less than 20 base pairs) is often shorter
than those produced via Sanger sequencing. Up to 96 runs
can be performed in parallel.
Next-generation DNA sequencing
NGS platforms involve massively parallel sequencing of
bulks of clonally amplified DNA molecules that are spatially
separated and have helped to shift the focus of sequence anal-
ysis from a few loci to multiple genes and loci. With NGS,
each run can give the nucleotide sequence for several loci and
several tumor samples. Importantly, NGS methods can detect
any variant from single-nucleotide changes to insertions or
deletions, and even translocations, in a single multiplex PCR
reaction. Depending on the depth of sequencing, the LOD of
NGS is about 1–5 %. Results are provided as quantitative
information. The most sensitive part of the NGS is the bioin-
formatic pipeline generating Binary Sequence Alignment
Map/Sequence Alignment Map format (BAM/SAM) files.
Specific statistical algorithms are used to score the quality of
a single read by aligning the sequence to a reference genome.
As a consequence, some readouts do not detect all of the
deletions, insertions, or other mutations that are detectable
with Sanger sequencing, as some mutations are found by the
basic algorithms but subsequently excluded and, therefore, do
not occur in the resulting variant caller files. Therefore, exten-
sive validation of the entire procedure is essential, as is the use
of internal control to assess the reproducibility of the runs.
With the increasing number of biomarkers, NGS allows
screening of a large number of patients and markers with a
fixed and limited amount of DNA. For NGS using Ion Torrent
technology, as little as 1 ng input material is needed, whereas
conventional sequencing technologies need 10 to 20 ng per
run and marker [57]. As a first step, a DNA library is gener-
ated by amplification of the DNA fragments to be sequenced
(the gene panel) in a single reaction (sometimes in up to five
different tubes) or capture hybridization followed by the am-
plification of this pre-library either by emulsion PCR
(emPCR; e.g., on spheres) or by bridge PCR on solid flow
cells [46]. As capture hybridization needs much more input
material compared with the panel-amplification approach, the
latter is mostly used in the analysis of biomarkers. Ultimately,
a single NGS run may comprise many millions or even bil-
lions of spatially distributed, clonally amplified amplicons
[58]. Custom assays can be developed (AmpliSeq™ for Ion
Torrent, GeneRead for Qiagen, TruSeq™ for Illumina) using
amplicons designed with a starting size of 150 bp, optimal for
FFPE samples. Finally, the quality of the sample can be ex-
tremely limited, and strategies have been proposed to identify
samples with low probability of success (e.g., the Illumina
FFPE QC Kit based on qPCR validation) before any NGS
run. This highlights that not all samples are suitable for anal-
ysis on these platforms.
Historically, three principal NGS technologies have been
commercially available [58]. The first of these, sequencing-
by-ligation, no longer has any clinical application. The second
is sequencing-by-synthesis [59], and the third is based on the
Table 2 Methods for enriching mutant DNA for RAS testing [49–53]
Method Features
Microdissection Allows precise analysis of tumor tissue by
reducing contamination with normal tissue
and, therefore, improving sensitivity for
RAS mutations present in the neoplastic cell
sample
COLD PCR Exploits the critical temperature at which
mutation-containing DNA is preferentially
melted over WT (sensitivity, 0.01–10 %)
Allele-specific
amplification
Uses primers designed with a 3′ terminal
nucleotide that pairs with the mutant
sequence but not with the WT (e.g., the
amplification refractory mutation system)
(sensitivity, 0.1–1 %)
Blocking amplification
of WT sequence
For example, by binding high-affinity peptide
nucleic acid probes (PCR clamp; sensitivity
in routine applications, 0.1–1 %)
Selective destruction
of WT samples
Exploiting restriction enzyme sites in the WT
sequence (e.g., restriction endonuclease-
mediated selective PCR and simultaneous
PCR/restriction fragment length
polymorphism) (sensitivity, 0.001–0.1 %)
COLD co-amplification at lower denaturation temperatures, PCR poly-
merase chain reaction, WTwild-type
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pyrosequencing approach. As an alternative to pyrophosphate
measurement, hydrogen ions/protons can be used as a hydro-
gen ion is released for each nucleotide incorporated. These can
be measured as an induced currency peak on a negatively
charged semiconductor, which is the basis of the detection unit
or chip. Currently available NGS platforms are summarized in
Table 3.[60–62] Of these, the Illumina MiSeq and Life
Technologies’ Ion Torrent Personal Genome Machine™
(PGM™) are the most commonly used in Europe (H. Van
Krieken, personal communication), and NGS sequencing
methods are expected to replace older methods completely
in the coming years.
MiSeq (Illumina Sequencing Systems)
MiSeq is based on a sequencing-by-synthesis approach [59],
using fluorescently labeled reversible-terminator nucleotides
and clonally amplified DNA templates on acrylamide-coated
glass flow cells [63]. Originally, MiSeq was developed as a
modification of the earlier Genome Analyzer and HiSeq ma-
chines and was designed for lower throughput and fast-
turnaround appropriate for smaller laboratories and clinical
diagnostics. The MiSeqDx is a special type of MiSeq devel-
oped for clinical analysis [63, 64]. The error rate of the
Illumina technology is estimated to be <0.4 % [63, 65].
More recently, Illumina has introduced the NextSeq system,
which is broadly similar to MiSeq, although the run time is
faster (12–30 versus 5–55 h for MiSeq) [61].
Ion Torrent (Life Technologies)
The Ion Torrent PGM™ sequencer is based on ion semicon-
ductor technology [66]. DNA fragments are clonally amplified
by emulsion PCR on the surface of 3-μm diameter beads,
which are then loaded into wells on a proton-sensing silicon
wafer. PGM™ was the first commercial sequencing machine
that did not require fluorescence and camera scanning, resulting
in higher speed, lower cost, and smaller instrument size [64].
The error rate with Ion Torrent sequencing has been estimated
at 1.8–1.9% [63, 65], mostly because of higher error rates in the
detection of homopolymer stretches. Ion Torrent sequencing
has been recently used to assess RAS status of colorectal carci-
noma tumors in the CAPRI-GOIM clinical trial [57], and a
panel of well-known predictive markers in the receptor tyrosine
kinase pathway, including KRAS and NRAS, has been devel-
oped by the OncoNetwork Consortium [67].
Hypersensitive methods
For the detection of single mutation events in a background of
WT sequences, digital PCR techniques [68] were developed
that can achieve LODs of <0.1 % for specific hotspots. If the
coverage, and thus the depth, of NGS techniques are in-
creased, they can also reach similar LODs [69]. Sensitivity
can also be increased by using single-molecule techniques that
discriminate between biological and technical duplicates, such
as single-molecule molecular inversion probes [70].
The potential applications for hypersensitive methods in-
clude detection of mutations in circulating plasma DNA (the
so-called liquid biopsy), monitoring of metastatic disease un-
der therapy, detection of emergence of resistance to targeted
agents, analysis of small or poor-quality DNA samples, and as
a possible additional parameter alongside histopathology for
the staging of tumors [71]. Such approaches have been applied
in research and for free plasma DNA detection; there will be
no direct application for molecular RAS testing in routine clin-
ical practice until the clinical validity of these techniques can
be determined. The preparation of such assays is generally
easier than for NGS assays, but the scope of the targeted
markers is greatly reduced, mostly focusing on a single gene
locus or small number of loci.
BEAMing
BEAMing (beads, emulsions, amplification, and magnetics)
[72] has been used for RAS analysis of samples from clinical
trials of EGFR inhibitors [73, 74]. Single DNA molecules are
attached to single magnetic beads and are amplified by using
emPCR, resulting in beads spiked with thousands of clonally
identical PCR products. These are hybridized with mutation-
specific probes coupled to different fluorochromes, which are
then counted by fluorescence-activated cell sorting (FACS).
Overall, BEAMing is more suited to the detection of fewer
hotspot variants and has the disadvantage that only limited
information can be retrieved, which depends mostly on the
amount of available fluorochromes and the filter sets of the
Table 3 Examples of currently
available next-generation
sequencing platforms
Principle Amplification
454 (Roche) [60] Pyrosequencing Emulsion PCR
Junior (Roche) Pyrosequencing Emulsion PCR
HiSeq/MiSeq (Illumina) [61] Reversible termination Bridge PCR
Ion Torrent (Life Technologies) [62] Semiconductor sequencing Emulsion PCR
PCR polymerase chain reaction
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FACS device. In most cases, up to four different events can be
analyzed per run, which limits the width of the detection. A
single nucleotide can be analyzed per test (e.g., the nucleotide
34 position in KRAS); therefore, for detection of mutations in
positions 34, 35, and 38, three BEAMing reactions are neces-
sary. Detection of all three positions (34, 35, and 38) in a
single BEAMing reaction can be achieved only by using one
fluorochrome each for the WTsequence at nucleotides 34, 35,
and 38, and at the expense of knowing the exact type of alter-
ation (e.g., c.34G>A). Although the sensitivity of BEAMing
is 0.01 %, it must be emphasized that a cutoff of 5 % mutant
alleles in tumor samples has been adopted when this technol-
ogy has been used in clinical trials [73, 74].
Droplet Digital PCR
Droplet Digital PCR (ddPCR) techniques involve compart-
mentalization of DNA, again using emPCR. Clonally ampli-
fied PCR products of an original single DNA fragment are
contained in the micelles of a water-in-oil emulsion [75, 76],
together with mutation-specific probes that can be obtained
from TaqMan® assays (Applied Biosystems). These droplets
are counted directly by flow cytometry. This approach can be
multiplexed (up to seven in a single run) so, as with
BEAMing, multiple runs are necessary to cover the multiple
genetic variations of KRAS and NRAS. The ddPCR detection
unit is, however, easier to work with than the BEAMing unit
as the ddPCR products can be measured directly without the
additional steps requiredwhen using the BEAMing technique.
ddPCR techniques in association with liquid biopsies show
considerable potential, although their precise clinical role is
currently unclear [71].
Approved in vitro diagnostic tools for RAS testing
Commercially available kits, instruments, and reagents that
are intended by the manufacturer to be used for in vitro exam-
ination of patient specimens for the purpose of providing in-
formation are governed by European Directive 98/79/EC on
in vitro medical devices [77]. Key objectives of this directive
are to ensure that in vitro diagnostic medical devices provide a
high level of health protection and attain the attributed perfor-
mance level, and products that conform to this standard carry
“CE” marking. The directive does not regulate products for
research-use only nor does it cover non-commercialized pa-
tient diagnostic tools produced within health institution labo-
ratories for use solely within that environment. It is important
to note that the CE mark simply means that the product itself
has consistent quality and does not provide any information
about specificity and sensitivity in the lab where the kit is
used.
The advantage of commercial CE tests is the validation
process that they have undergone. Thus, after the in-house
verification of a CE-kit, no additional testing is needed, which
is in contrast to non-CE-kits where a change in the batch of
materials used requires quality testing of the new material. A
list of CE-approved RAS tests available in Europe (complete
as of December 2014, to the best of our knowledge) is shown
in Table 4 [78–92]. Some techniques identify the somatic mu-
tation directly, while others are screeningmethods that involve
a two-step process for positive samples. In addition, other CE-
approved kits are available for assessing KRAS exon 2 status
(with or without exon 3 codon 61), and laboratories may wish
to use these, supplemented with laboratory-developed tests to
complete the RAS analysis.
Of the available CE-approved kits, only five detect muta-
tions in both the KRAS and NRAS genes: (1) CRC RAScan™
(SURVEYOR®/WAVE®), (2) CRC RASseq™ (both
Transgenomics, Inc.), (3) Therascreen® KRAS and NRAS
Pyro® kits (Qiagen), (4) OncoCarta (Agena Bioscience), and
(5) cobas® KRAS mutation test (Roche) together with
LightMix® kits (TIB MOLBIOL) for the cobas system.
CRC RAScan™ (SURVEYOR®/WAVE®) uses
Transgenomics’ proprietary DNA mismatch-cutting enzyme
SURVEYOR® nuclease, with cleavage products separated by
denaturing high-pressure liquid chromatography using the
WAVE® platform [77]. The nature of the mutation is then
confirmed by Sanger sequencing. CRC RASseq™ uses
Transgenomics’ proprietary primer sets for PCR amplification
and Sanger sequencing of exons 2, 3, and 4 of the KRAS and
NRAS genes [79]. This method was used to identify RAS mu-
tation status in mCRC patients included in the PRIME study
[14].
Therascreen® KRAS and NRAS Pyro® kits are based on
pyrosequencing technology and consist of two assays: one
for codons 12 and 13 and a second for codon 61 [80, 81].
Qiagen has recently launched a new RAS Extension Pyro
Kit, covering codons 58/59, 117, and 146 of KRAS and
NRAS, which has recently received CE-marked status, al-
though the LOD of this extension kit is not reported [93].
The Agena Bioscience OncoCarta panel includes 12 KRAS
and eight NRAS mutations [82]. Detection is based on the
Agena MassARRAY® system, which uses matrix-assisted la-
ser desorption/ionization–time of flight mass spectrometry
[94].
The cobas® system works on the basis of high-resolution
melting using different PCR reactions together with mutation-
specific probes coupled with different fluorochromes using
the real-time PCR cobas 480® (Roche) device. After the gen-
eration of PCR products, these are melted in a temperature
gradient. The melting point of the mutation-specific probe
indicates the type of mutation, being specific for either the
codon (cobas® KRAS mutation test) or the position
(LightMix® kits).
The choice of CE-marked RAS mutation test by individual
laboratories is largely dependent on the available equipment,
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experience, and costs of the test [95]. The rapid change in
knowledge of biomarkers and loci implies that development
of additional commercial kits is necessary, and the situation
for RAS screening, with only five available kits covering all
loci, highlights the relatively low reactivity of the market.
Laboratory-developed methods
Many laboratory-developed methods for RAS testing are used
for in vitro diagnostics, and still more methods exist for
research-use only [42]; the latter are beyond the scope of this
review. This is especially true for NGS, as commercially avail-
able kits are almost inaccessible, particularly those of CE-
quality. CE-marked assays for NGS could be the next step to
ensure the quality of reagents and primer pools. Initiatives to
standardize a primer set, such as the community panel from
Life Technologies and the Ion AmpliSeq™ Colon and Lung
Cancer Research Panel v2, are underway, although such prim-
er sets are currently for research-use only [57]. Most common-
ly, Sanger sequencing- and pyroseqencing-based laboratory-
developed methods are used for RAS testing [43]. In some
countries, such as France, allele-specific PCR is very popular
(Dequeker et al., manuscript submitted). Here, mutant alleles
are selectively amplified, making this technique highly sensi-
tive for the detection of mutations in the RAS genes. There are
many different variations of this general principle (Table 5)
[96–100], which is reflected in the many variations of allele-
specific hybridization methods [43]. In general, laboratory-
developed methods offer the possibility of more rapid adapta-
tion to new knowledge of biomarkers and loci, although their
use requires a high level of experience and quality manage-
ment within the laboratory. Moreover, mostly as a result of the
costs of CE-marked kits, laboratory-developed techniques are
very suitable for testing the sensitivity (LOD) and specificity
of RAS mutation detection, which is important in the mainte-
nance of quality.
Sensitivity of RAS testing
The sensitivity of mutation detection is influenced by
multiple factors, mostly LOD and the minimum amount
of required template. The LOD is dependent on the tech-
nique used and might therefore be considered as the tech-
nical sensitivity, which is defined by the ratio of the
Table 4 CE-approved RAS-testing kits available in Europe
In vitro diagnostic kit KRASa NRASa Mutant enrichment Detection method LOD (%)b
CRC RAScan™ (SURVEYOR®/WAVE®) [78] Yes Yes None Mismatched heteroduplex cleavage
and DHPLCc
2–5
CRC RASseq™ [79] Yes Yes None Sanger sequencing 5–10
Therascreen® KRAS and NRAS Pyro [80, 81] Yes Yes None Pyrosequencing 1–7
Agenad OncoCarta™ [82, 83] Yes Yes None Mass spectrometry 5–10
LightMix® NRAS ex2–4 KRAS ex4 [90] Yes Yes PCR clamp (LNA) Melting curve analysis-based 1
Therascreen® KRAS RGQ PCR [84] Yes No Allele-specific probes RT-PCR 1–6
cobas KRAS mutation test [85] Yes No PCR clamp (TaqMelt™) Melting curve analysis-based 5
Randox biochip array [86] Yes No None Array hybridization 1
INFINITI® KRAS [87] Yes No None Array hybridization NS
KRAS StripAssay® [88] Yes No PCR clamp (blocker) Strip hybridization 1
EnteroGen® KRAS [89] Yes No Allele-specific probes RT-PCR <1
LightMix® KRAS codon 12/13 [90] Yes No PCR clamp (LNA) Melting curve analysis-based 1
PNAClamp™ [91] Yes No PCR clamp (PNA) RT-PCR <1
RealQuality RI-KRASMuST [92] Yes No Allele-specific probes RT-PCR 1
DHPLC denaturing high-pressure liquid chromatography, LNA locked nucleic acid, LOD limit of detection, NS not specified, PCR polymerase chain
reaction, PNA peptide nucleic acid, RT-PCR reverse transcriptase polymerase chain reaction
aMethods may not include all exons or relevant codons
bDetermination methods may vary
c Confirmation by DNA sequencing recommended
d Formerly Sequenom
Table 5 Allele-specific polymerase chain reaction (PCR) methods for
RAS testing
Amplification refractory mutation system (ARMS) [96]
Restriction endonuclease-mediated selective (REMS) PCR [97]
Fluorescent amplicon generation (FLAG) [98]
Restriction fragment length polymorphisms (RFLP) [99]
Allele-specific ligation detection reaction [100]
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measurement signal (mutation) to the background signal
(mutant signal in a WT sample) [43]. The sensitivities of
available tests range from <1 to 10 % for CE-approved
testing methods (Table 4). For laboratory methods, the
most sensitive techniques are allele-specific PCR and hy-
bridization assays (0.1–1 %) and gel electrophoresis (e.g.,
temporal temperature gradient or constant denaturant cap-
illary electrophoresis) (1 %) [43]. Pyrosequencing (5 %),
high-resolution melting curve analysis (~10 %), and
Sanger sequencing (10–25 %) have a lower level of tech-
nical sensitivity [43, 101]. This highlights the benefit of
histopathology as the basis of mutation detection:
sensitivity can be controlled, as the total amount of
tissue—reflecting the amount of template, and relative
fraction of neoplastic cells within the tumor (measured
as area or total nuclei)—reflecting the LOD, can be deter-
mined (semi) quantitatively. For example, a KRAS muta-
tion in a small metastatic focus of neoplastic cells in a
lymph node can escape detection when entire tissue sec-
tions of the lymph node are used for DNA isolation (i.e.,
normal cell DNA content is far greater than neoplastic cell
DNA). After careful microdissection of the neoplastic
cells, however, the KRAS mutation can unequivocally be
identified. Thus, in clinical practice, the sensitivity of the
entire process must be considered, not just the sensitivity
of the technique being used.
Unfortunately, the sensitivity of mutation detection—
which needs to be related to the clinical effect—in the
reference studies establishing the validity of RAS as a bio-
marker is unknown. This is because only the technical sen-
sitivity of detection can be derived from the method used
and the minimum required neoplastic cell fraction required
as input, not the actual values for individual samples. Thus,
the clinical significance of high versus lower sensitivity,
indicating the number of neoplastic clones with or without
a RAS mutation, is currently unclear. Achievement of
higher sensitivity must, therefore, be weighed against the
possibility of false positives or the identification of muta-
tions present only in a small minority of the neoplastic
cells, reflecting a small tumor clone population with RAS
mutations, which is of unknown clinical relevance.
Additionally, sensitivity depends on the experience of the
laboratory, as results for the LOD of Sanger sequencing
were found to be similar to allele-specific methods during
blind testing [102]. Furthermore, a recent publication sug-
gests that tumors containing <1 % mutant KRAS DNA
allele-fraction in microdissected samples might still benefit
from treatment with anti-EGFR agents [103]. Overall, it is
important to take into account histopathological informa-
tion from the tissue samples used for mutation detection in
future clinical studies, to better define cutoffs for sensitiv-
ity and clinical response, and to improve the benefit to
patients of targeted therapies.
Timing of testing
Turnaround times for testing remain a key challenge for pathol-
ogists and oncologists, and it is important that a strategy is in
place to optimize the process, whether this is through stratified
reflex testing based on patient risk factors or through logistical
management of new or archived tumor samples. In general,
European EQA schemes recommend that the process of
obtaining aRAS test result should take nomore than 10working
days [104], and it is important that pathology and oncology
centers work together to address barriers that prevent prompt
turnaround of test requests. NGS processes generally take more
than 2 days to complete, which is the main bottleneck when
choosing new technology in comparison to conventional
methods.
Reflex sampling involves the immediate sampling and test-
ing of mCRC at the time of diagnostic biopsy. The major
benefit of reflex testing is that information on RAS status is
available as soon as EGFR-targeted therapies are considered,
so no time is lost in starting treatment. Reflex testing in which
all colorectal cancers are tested to anticipate the risk of metas-
tasis is also possible, although this remains an area of debate.
Underlying RAS mutations appear to occur early in tumor
development, and therefore, testing for RAS mutations is po-
tentially informative, although the prognostic significance of
such information is not known.While delays in obtaining RAS
test results can affect treatment strategies, the implementation
of reflex testing is likely to be associated with a high degree of
unnecessary testing. Whatever the timing of testing, it is im-
portant that interpretation of results must take into account the
patient’s clinical history.
Bioinformatics
The function of the bioinformatics pipeline with regard to RAS
analysis is to convert the raw sequencing data into clinically
useful information through the use of appropriate software
algorithms [105]. Integration of NGS technologies into the
clinical setting has the potential to verify suggestive relation-
ships and remove ambiguity more quickly than current ap-
proaches. Validation of the output from such algorithms can
be achieved through the use of reference sequences, control
samples containing specific RAS variants, and by comparing
the output with that from alternative sequencing platforms.
Guidelines issued by the National Collaborative Study of
Dutch Genome Diagnostic Laboratories state that data analy-
sis and quality checks can be divided into fivemain steps: base
calling and quality assessment of raw data, mapping of reads
against a given reference sequence, enrichment analysis, cov-
erage analysis, and variant calling and annotation [106]. The
guidelines further state that minimal quality criteria must be
established in each laboratory to determine the overall quality
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of platform performance, although the specific criteria usually
depend on the sequencing platform being used.
The initial RAS sequencing report should include all vari-
ants that were detected against a stated reference sequence,
regardless of their clinical significance, although this informa-
tion should be used to annotate each variant as far as possible
(including whether or not clinical validation has been reported
[105]. The report should also include information on the test
used, including any important limitations, along with base
quality scores and confirmatory testing. Notably, a study of
genome sequencing across 30 international groups showed
that, while there was generally good consistency across bio-
informatics analysis and interpretation, there was a lack of
concordance with regard to interpretation, report content,
and patient consent procedures [107]. Suggested reasons for
differences between groups included limited quality control
measures; different read aligners and variant calling pipelines;
variations in performance of analysis tools, software, and fil-
ters; errors in programming or manual analysis; and poor-
quality data [105, 107].
The role and importance of quality assurance programs
Given the large variety of techniques and the importance of
laboratories’ experience, it is essential to test and validate
centers’ performance with standardized EQA schemes. Use
of CE-marked kits or fully validated methods involves proof
that quality is maintained after the implementation of the
marker in the laboratory. Nevertheless, EQAvalidation should
be done periodically to obtain assurance about the laboratory’s
quality.
Guideline recommendations for a European EQA program
to ensure accuracy and proficiency in KRAS mutation testing
were published in 2008 [42]. A number of EQA programs are
now available (Table 6), [42, 108–114] such as the European
program established by the European Society of Pathology
(ESP) for testing biomarker mutations in colorectal cancer
[42] or the German Quality Initiative in Pathology (QuIP)
(Jung et al., manuscript in preparation). The European pro-
gram aims to ensure optimal accuracy and proficiency in bio-
marker testing in colorectal cancer across all participating
countries [115] and is organized in collaboration with a
European working group and the Biomedical Quality
Assurance Research Unit of the University of Leuven [115].
The program provides recommendations and overviews of
laboratory methods, standardized operating procedures, and
accreditation criteria relevant for RAS mutation testing [42,
115, 116].
The Organization for Economic Co-operation and
Development (OECD) guidelines for Quality Assurance in
Molecular Genetic Testing address processes relating to ge-
netic testing for variations in germline DNA sequences that
are also applicable to somatic DNA testing. The guidelines
cover general principles and best practices, EQA systems,
proficiency testing (monitoring the quality of laboratory per-
formance), quality of result reporting, and education and train-
ing standards for laboratory personnel [117].
In March 2012, medical oncologists, pathologists, geneti-
cists, molecular biologists, EQA providers and representatives
from pharmaceutical industries developed a guideline to har-
monize the standards applied by EQA schemes in molecular
pathology. The guideline comprises recommendations on the
organization of an EQA scheme, defining the criteria for ref-
erence laboratories, requirements for EQA test samples, and
the number of samples that are needed for an EQA scheme
[118]. All EQA schemes should be developed by an expert
group with a representing EQA provider, which is also re-
sponsible for all organizational aspects and operation of the
scheme according to International Organization for
Standardization (ISO) 17043 standards. For each scheme, a
team coordinator is responsible for the selection, distribution
and receipt of cases, and the analysis and reporting of results.
Importantly, the samples used in an EQA scheme should re-
flect the diagnostic and clinical reality as closely as possible,
and the turnaround time, as defined by the EQA provider,
should reflect the common clinical situation. For a reliable
evaluation, at least 10 samples per laboratory need to be ana-
lyzed per year and can be provided in a single batch, or in
multiple smaller batches. The limit for poor performance
should be defined as a score 18 out of 20, with no false-
positive or false-negative results. Finally, EQA providers
should be encouraged to make the general reports available
in the public domain. The ESP Colon EQA scheme is orga-
nized in accordance with these recommendations and with the
OECD best practice guidelines [42]. OECD Principles of
Good Laboratory Practice state that individual testing facilities
should have a documented QA program to ensure that studies
performed are in compliance with principles of good labora-
tory practice [119]. A number of authors have stated that par-
ticipation in internal QA schemes, as well as external schemes,
should be mandatory for diagnostic pathology laboratories
Table 6 Quality assurance programs for RAS testing in colorectal
cancer
AIOM-SIAPEC Italian Program for EQA in molecular pathology [112]
College of American Pathologists [108]
European Molecular Genetics Quality Network [110]
European Society for Pathology [42]
Gen&Tiss French Program–French Cancer Institute (INCa)–AFAQAP–
GFCO [113, 114]
German Society for Clinical Chemistry and Laboratory Medicine [111]
German Society for Pathology–QuIP (Quality Initiative Pathology)a
United Kingdom National External Quality Assessment Service [109]
a Jung et al. manuscript in preparation
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[95, 120]. Furthermore, the validation or verification of testing
methods is a formal requirement for the accreditation of labo-
ratories according to the major international standard applica-
ble to medical testing laboratories: ISO 15189 [121, 122].
The need for QA schemes was highlighted by recent re-
search carried out under the European QA program [45], in
which 27 % of participating laboratories genotyped at least
10 % of samples incorrectly, although <5 % of distributed
specimens overall were genotyped incorrectly. Errors included
false negatives, false positives, and incorrectly genotyped mu-
tations. In addition, 20 % of laboratories reported a technical
error for at least one sample. It is encouraging, however, that
the majority of laboratories made no mistakes. There are now
sufficient quality-assured laboratories to allow RAS testing
across Europe, and even a small number of EQA rounds can
improve quality to a high level [123].
In the future, as new techniques become routinely avail-
able, existing EQA programs will need to evolve to address
the issues arising from the use of NGS and other increasingly
sensitive techniques.
Conclusions
Pathologists have a key role to play in ensuring that patients
receive optimal and appropriate treatment for mCRC. Up-
front tumor RAS testing—rather than solely KRAS exon 2
testing—is critical for patients with mCRC, as RASmutations
predict a lack of response to anti-EGFR therapy [14]. The
more extensive use of biomarkers is already included in rele-
vant treatment guidelines from ESMO, the NCCN, and the
AIO [38, 39, 41] and is increasingly recognized as an essential
component of mCRC diagnosis and work-up. The reference
methods are sequencing: initially the Sanger method and sub-
sequently pyrosequencing.More recently, NGS techniques for
mutational analysis have been developed, the key methods
applied to molecular pathology being parallel semiconductor
and reversible termination sequencing. Some CE-approved
kits are commercially available, but most apply only to
KRAS. Only five kits currently cover both KRAS and NRAS
genes, although even these do not yet include all potentially
relevant mutations. Further kit development should be more
flexible to allow for evolution of new biomarkers. In addition,
many laboratories have their own in-house methods for
assessing mutational status and have the ability to more rap-
idly adapt testing to clinically validated biomarkers. The dif-
ferent analysis techniques have differing technical sensitivities
for detecting mutations, although the ideal process sensitivity
threshold—including that relating to the neoplastic cell bur-
den in the sample—and the value of tests with a very high
sensitivity are currently unknown. More comprehensive plan-
ning of clinical studies in the future is therefore required.
Appropriate tumor sampling and prompt delivery of material
to diagnostic laboratories is critical for accurate and timely RAS
testing. Processes to ensure that the turnaround time from sample
request to RAS evaluation is as efficient as possible need to be
implemented on a national and center-specific level to ensure that
patients have the option to receive themost appropriate treatment.
EQA programs play an important role in ensuring that RAS
testing is carried out to a high standard, especially when
laboratory-developed methods are used. EQA testing should
include “difficult” samples that are at the LOD of the assay
being used and should also test the entire chain of analysis, as
there are many different steps involved, from preparation of
the FFPE block and DNA to the actual molecular testing,
results, and bioinformatic reports.
Finally, RAS testing is still a moving field, and important
future directions include the extension of NGS to an increased
number of biomarkers and the extension of quantitative
methods to include circulating plasma DNA.
Acknowledgments Medical writing assistance with this manuscript
was provided by Daniel Booth, PhD (Bioscript Medical, UK) and funded
by Amgen (Europe) GmbH.
Authors’ contributions All authors were involved in critically
reviewing the manuscript at every stage of development and in the deci-
sion to submit the manuscript for publication.
Compliance with ethical standards
Conflict of interest JHJM Van Krieken has participated in advisory
boards for Amgen, Merck Serono, GlaxoSmithKline, and Sakura
and has received honoraria and research grants from these compa-
nies. N Normanno has participated in advisory boards for Amgen,
AstraZeneca, Merck Serono, and Roche. MJL Ligtenberg has re-
ceived research funding from Amgen and AstraZeneca and has par-
ticipated in advisory boards for AstraZeneca. E Rouleau has re-
ceived research funding from Amgen and Roche and honoraria from
AstraZeneca and GlaxoSmithKline. SD Patterson is a stockholder
and former employee of Amgen Inc. A Jung has participated in
advisory boards and received honoraria from Amgen, AstraZeneca,
Boehringer, Celgene, GlaxoSmithKline, Merck Serono, Pfizer,
Qiagen, and Roche.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Heinemann V, Douillard JY, Ducreux M, Peeters M (2013)
Targeted therapy in metastatic colorectal cancer—an example of
personalised medicine in action. Cancer Treat Rev 39:592–601
2. Vijayaraghavan A, Efrusy MB, Goke B, Kirchner T, Santas CC,
Goldberg RM (2012) Cost-effectiveness of KRAS testing in
392 Virchows Arch (2016) 468:383–396
metastatic colorectal cancer patients in the United States and
Germany. Int J Cancer 131:438–445
3. Biomarkers Working Group (2001) Biomarkers and surrogate end-
points: preferred definitions and conceptual framework. Clin
Pharmacol Ther 69:89–95
4. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S,
Coebergh JW, Comber H, Forman D, Bray F (2013) Cancer inci-
dence and mortality patterns in Europe: estimates for 40 countries
in 2012. Eur J Cancer 49:1374–1403
5. Siddiqui AD, Piperdi B (2010)KRASmutation in colon cancer: a mark-
er of resistance to EGFR-I therapy. Ann Surg Oncol 17:1168–1176
6. Lièvre A, Artru P, GuiuM, Laurent-Puig P, Merlin JL, Sabourin JC,
Viguier J, Bastie A, Seronde A, Ducreux M (2013) The KRAS
mutation detection within the initial management of patients with
metastatic colorectal cancer: a status report in France in 2011. Eur J
Cancer 49:2126–2133
7. Amado RG,WolfM, Peeters M, Van Cutsem E, Siena S, Freeman DJ,
Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD
(2008) Wild-type KRAS is required for panitumumab efficacy in pa-
tients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634
8. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel
M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F,
Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, et al.
(2010) Randomized, phase III trial of panitumumab with infusional
fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus
FOLFOX4 alone as first-line treatment in patients with previously
untreated metastatic colorectal cancer: the PRIME study. J Clin
Oncol 28:4697–4705
9. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko
Y, Andre T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G,
Ciuleanu TE, Roman L, Van Cutsem E, et al. (2010) Randomized
phase III study of panitumumab with fluorouracil, leucovorin, and
irinotecan (FOLFIRI) compared with FOLFIRI alone as second-
line treatment in patients with metastatic colorectal cancer. J Clin
Oncol 28:4706–4713
10. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR,
Makhson A, D’Haens G, Pinter T, Lim R, Bodoky G, Roh JK,
Folprecht G, Ruff P, Stroh C, Tejpar S, et al. (2009) Cetuximab
and chemotherapy as initial treatment for metastatic colorectal can-
cer. N Engl J Med 360:1408–1417
11. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP,
Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S,
Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F (2011)
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-
line treatment for metastatic colorectal cancer: updated analysis of
overall survival according to tumor KRAS and BRAF mutation
status. J Clin Oncol 29:2011–2019
12. Peeters M, Oliner KS, Price TJ, Cervantes A, Sobrero AF, Ducreux
M, Hotko Y, Andre T, Chan E, Lordick F, Punt CJA, Strickland A,
Wilson G, Ciuleanu T-E, Roman L, et al. (2014) Analysis of
KRAS/NRAS mutations in phase 3 study 20050181 of
panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-
line treatment (tx) of metastatic colorectal cancer (mCRC). J Clin
Oncol 32 (Suppl 3):Abstract #LBA387
13. Tejpar S, Peeters M, Gelderblom H, Humblet Y, Vermoken J, De
Hertogh G, Nippgen J, von Heydebreck A, Stroh C, Van Cutsem E
(2008) Relationship of efficacywith KRAS status (wild type [wt] vs
mutant [mt]) in patients with irinotecan-refractory metastatic colo-
rectal cancer (mCRC), treated with irinotecan and escalating doses
of cetuximab: preliminary data from the EVEREST study. Ann
Oncol 19 (Suppl 8):viii125 (Abstract #358P)
14. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel
M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F,
Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, et al.
(2013) Panitumumab-FOLFOX4 treatment and RAS mutations in
colorectal cancer. N Engl J Med 369:1023–1034
15. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio
J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH,
Zubel A, Koralewski P (2009) Fluorouracil, leucovorin, and
oxaliplatin with and without cetuximab in the first-line treatment
of metastatic colorectal cancer. J Clin Oncol 27:663–671
16. Pritchard CC, Grady WM (2011) Colorectal cancer molecular biol-
ogy moves into clinical practice. Gut 60:116–129
17. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-
Kaiser U, Al-Batran SE, Heintges T, Lerchenmuller C, Kahl C,
Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J,
Scholz M, et al. (2014) FOLFIRI plus cetuximab versus FOLFIRI
plus bevacizumab as first-line treatment for patients with metastatic
colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Lancet Oncol 15:1065–1075
18. Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht
JR,YuH,OlinerKS,GoWY(2014) PEAK: a randomized,multicenter
phase II study of panitumumab plus modified fluorouracil, leucovorin,
and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in
patients with previously untreated, unresectable, wild-type KRAS exon
2 metastatic colorectal cancer. J Clin Oncol 32:2240–2247
19. Peeters M, Oliner KS, Parker A, Siena S, Van Cutsem E, Huang J,
Humblet Y, Van Laethem JL, Andre T, Wiezorek J, Reese D,
Patterson SD (2013) Massively parallel tumor multigene sequencing
to evaluate response to panitumumab in a randomized phase III study
of metastatic colorectal cancer. Clin Cancer Res 19:1902–1912
20. Peeters M, Douillard JY, Van Cutsem E, Siena S, Zhang K,
Williams R, Wiezorek J (2013) Mutant KRAS codon 12 and 13
alleles in patients with metastatic colorectal cancer: assessment as
prognostic and predictive biomarkers of response to panitumumab.
J Clin Oncol 31:759–765
21. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu
D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van
Cutsem E, O’Callaghan CJ, Khambata-Ford S, Zalcberg JR,
Simes J, et al. (2010) Association of KRAS p.G13D mutation with
outcome in patients with chemotherapy-refractory metastatic colo-
rectal cancer treated with cetuximab. JAMA 304:1812–1820
22. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B,
Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-
Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini
G, et al. (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA
mutations on the efficacy of cetuximab plus chemotherapy in
chemotherapy-refractory metastatic colorectal cancer: a retrospec-
tive consortium analysis. Lancet Oncol 11:753–762
23. Andre T, Blons H, Mabro M, Chibaudel B, Bachet JB, Tournigand C,
Bennamoun M, Artru P, Nguyen S, Ebenezer C, Aissat N, Cayre A,
Penault-Llorca F, Laurent-Puig P, de Gramont A; GERCOR (2013)
Panitumumab combined with irinotecan for patients with KRAS wild-
type metastatic colorectal cancer refractory to standard chemotherapy: a
GERCOR efficacy, tolerance, and translational molecular study. Ann
Oncol 24:412–419
24. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L,
Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I,
Bencardino K, Galluccio N, Catalano V, Tonini G, et al. (2009)
KRAS codon 61, 146 and BRAF mutations predict resistance to
cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type
metastatic colorectal cancer. Br J Cancer 101:715–721
25. Peeters M, Oliner KS, Price TJ, Cervantes A, Sobrero AF, Ducreux
M, Hotko Y, Andre T, Chan E, Lordick F, Punt CJA, Strickland A,
WilsonG, Ciuleanu TE, Roman L, et al. (2014) Updated analysis of
KRAS/NRAS and BRAF mutations in study 20050181 of
panitumumab (pmab) plus FOLFIRI for second-line treatment (tx)
of metastatic colorectal cancer (mCRC). Poster presented at ASCO
2014
26. Patterson SD, Peeters M, Siena S, Van Cutsem E, Humblet Y, Van
Laethem JL, Andre T, Tian Y, Sidhu R, Oliner KS (2013)
Comprehensive analysis of KRAS and NRAS mutations as
Virchows Arch (2016) 468:383–396 393
predictive biomarkers for single agent panitumumab (pmab) re-
sponse in a randomized, phase III metastatic colorectal cancer
(mCRC) study (20020408). J Clin Oncol 31:3617(Abstract)
27. Seymour MT, Brown SR, Middleton G, Maughan T, Richman S,
Gwyther S, Lowe C, Seligmann JF, Wadsley J, Maisey N, Chau I,
Hill M, Dawson L, Falk S, O’Callaghan A, et al. (2013)
Panitumumab and irinotecan versus irinotecan alone for patients
with KRAS wild-type, fluorouracil-resistant advanced colorectal
cancer (PICCOLO): a prospectively stratified randomised trial.
Lancet Oncol 14:749–759
28. Van Cutsem E, Lenz HJ, Köhne CH, Heinemann V, Tejpar S,
Melezínek I, Beier F, Stroh C, Rougier P, van Krieken JH,
Ciardiello F (2015) Fluorouracil, leucovorin, and irinotecan plus
cetuximab treatment and RAS mutations in colorectal cancer. J
Clin Oncol 33:692–700
29. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT,
Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E,
Mitchell JK,Madi A, Jasani B, JamesMD, et al. (2011) Addition of
cetuximab to oxaliplatin-based first-line combination chemothera-
py for treatment of advanced colorectal cancer: results of the
randomised phase 3 MRC COIN trial. Lancet 377:2103–2114
30. Stintzing S, Jung A, Rossius L, Modest DP, Fischer von
Weikersthal L, Decker T, Kiani A, Al-Batran S-E, Vehling-Kaiser
U, Heintges T, Moehler M, Scheithauer W, Kirchner T, Heinemann
V (2014)Mutations within the EGFR signaling pathway: influence
on efficacy in FIRE-3—a randomized phase III study of FOLFIRI
plus cetuximab or bevacizumab as first-line treatment for wild-type
(WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) pa-
tients. J Clin Oncol 32 (Suppl 3):Abstract 445. Poster presented
at ASCO 2014
31. Bokemeyer C, Kohne C-H, Ciardiello F, Lenz H-J, Heinemann V,
Klinkhardt U, Beier F, Duecker K, Tejpar S (2014) Treatment out-
come according to tumor RAS mutation status in OPUS study pa-
tients with metastatic colorectal cancer (mCRC) randomized to
FOLFOX4 with/without cetuximab. J Clin Oncol 32 (Suppl 5s):
Abstract 3505. Poster presented at ASCO 2014
32. Peeters M, Kafatos G, Taylor A, Gastanaga V, Yu H, Oliner KS,
Hechmati G, Terwey J-H, van Krieken JH (2015) Prevalence of
RAS mutations among patients with metastatic colorectal cancer
by country and region in randomized clinical trials: a pooled anal-
ysis. Presented at ASCO-GI, San Francisco, CA, USA
33. Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon
RA, Karapetis CS (2015) Extended RAS mutations and anti-EGFR
monoclonal antibody survival benefit in metastatic colorectal can-
cer: a meta-analysis of randomized, controlled trials. Ann Oncol 26:
13–21
34. Amgen Europe BV (2013) Vectibix. EPAR product information.
Amgen Europe B.V., Breda
35. Merck KGaA (2009) Erbitux. EPAR product information. Merck
KGaA, Darmstadt
36. Finkelstein SD, Sayegh R, Christensen S, Swalsky PA (1993)
Genotypic classification of colorectal adenocarcinoma. Biologic
behavior correlates with K-ras-2 mutation type. Cancer 71:3827–
3838
37. Finkelstein SD, Sayegh R, Bakker A, Swalsky P (1993)
Determination of tumor aggressiveness in colorectal cancer by K-
ras-2 analysis. Arch Surg 128:526–531 discussion 531–522
38. National Comprehensive Cancer Network (2014) NCCN Clinical
Practice Guidelines in Oncology™. Colon cancer. V3. National
Comprehensive Cancer Network, Jamestown, PA
39. AIO (2013) Statement der AIO-KRK Leitgruppe für die
Antikörpertherapie in Kombination mit einer Chemotherapie.
Arbeitsgemeinschaft Internistische Onkologie in der Deutschen
Krebsgesellschaft e.V., Berlin
40. Landelijke Werkgroep Gastro Intestinale Tumoren (2014)
Algemeen. http://www.oncolinenl/colorectaalcarcinoom.
Accessed December 2014
41. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D (2014)
Metastatic colorectal cancer: ESMO Clinical Practice Guidelines
for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):
iii1–iii9
42. van Krieken JH, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman
FT, Quirke P, Flejou JF, Plato HT, De Hertogh G, Jares P, Langner
C, Hoefler G, Ligtenberg M, Tiniakos D, et al. (2008) KRAS mu-
tation testing for predicting response to anti-EGFR therapy for co-
lorectal carcinoma: proposal for an European quality assurance pro-
gram. Virchows Arch 453:417–431
43. Shackelford RE,Whitling NA,McNab P, Japa S, Coppola D (2012)
KRAS testing: a tool for the implementation of personalized med-
icine. Genes Cancer 3:459–466
44. Monzon FA, Ogino S, Hammond ME, Halling KC, Bloom KJ,
Nikiforova MN (2009) The role of KRAS mutation testing in the
management of patients with metastatic colorectal cancer. Arch
Pathol Lab Med 133:1600–1606
45. Tembuyser L, Ligtenberg MJ, Normanno N, Delen S, van Krieken
JH, Dequeker EM (2014) Higher quality of molecular testing, an
unfulfilled priority: results from external quality assessment for
KRAS mutation testing in colorectal cancer. J Mol Diagn 16:371–
377
46. Morey M, Fernandez-Marmiesse A, Castineiras D, Fraga JM,
Couce ML, Cocho JA (2013) A glimpse into past, present, and
future DNA sequencing. Mol Genet Metab 110:3–24
47. Tol J, Dijkstra JR, Vink-Borger ME, Nagtegaal ID, Punt CJ, van
Krieken JH, Ligtenberg MJ (2010) High sensitivity of both se-
quencing and real-time PCR analysis of KRAS mutations in colo-
rectal cancer tissue. J Cell Mol Med 14:2122–2131
48. Carotenuto P, Roma C, Rachiglio AM, Tatangelo F, Pinto C,
Ciardiello F, Nappi O, Iaffaioli RV, Botti G, Normanno N (2010)
Detection of KRASmutations in colorectal carcinoma patients with
an integrated PCR/sequencing and real-time PCR approach.
Pharmacogenomics 11:1169–1179
49. Milbury CA, Li J, Makrigiorgos GM (2009) PCR-based methods
for the enrichment of minority alleles and mutations. Clin Chem 55:
632–640
50. Carotenuto P, Roma C, Cozzolino S, Fenizia F, Rachiglio AM,
Tatangelo F, Iannaccone A, Baron L, Botti G, Normanno N
(2012) Detection of KRAS mutations in colorectal cancer with
Fast COLD-PCR. Int J Oncol 40:378–384
51. Parsons BL, Heflich RH (1997) Genotypic selection methods for
the direct analysis of point mutations. Mutat Res 387:97–121
52. Gocke CD, Benko FA, KopreskiMS, EvansDB (2000) Enrichment
methods for mutation detection. Ann N YAcad Sci 906:31–38
53. Chang YS, Er TK, Lu HC, Yeh KT, Chang JG (2014) Detection of
KRAS codon 12 and 13 mutations by mutant-enriched PCR assay.
Clin ChimActa 436C:169–175
54. Hoff KJ (2009) The effect of sequencing errors on metagenomic
gene prediction. BMC Genomics 10:520
55. Ibrahem S, Seth R, O’Sullivan B, Fadhil W, Taniere P, Ilyas M
(2010) Comparative analysis of pyrosequencing and QMC-PCR
in conjunction with high resolution melting for KRAS/BRAF mu-
tation detection. Int J Exp Pathol 91:500–505
56. Balzer S, Malde K, Jonassen I (2011) Systematic exploration of
error sources in pyrosequencing flowgram data. Bioinformatics
27:i304–i309
57. Ciardiello F, Normanno N, Maiello E, Martinelli E, Troiani T,
Pisconti S, Giuliani F, Barone C, Carteni G, Rachiglio AM,
Montesarchio V, Tonini G, Rizzi D, Cinieri S, Bordonaro R, et al.
(2014) Clinical activity of FOLFIRI plus cetuximab according to
extended genemutation status by next-generation sequencing: find-
ings from the CAPRI-GOIM trial. Ann Oncol 25:1756–1761
394 Virchows Arch (2016) 468:383–396
58. Moorthie S, Mattocks CJ, Wright CF (2011) Review of massively
parallel DNA sequencing technologies. HUGO J 5:1–12
59. Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton
J, Brown CG, Hall KP, Evers DJ, Barnes CL, Bignell HR, Boutell
JM, Bryant J, Carter RJ, Keira CR, Cox AJ, et al. (2008) Accurate
whole human genome sequencing using reversible terminator
chemistry. Nature 456:53–59
60. Roche (2014) The technology. http://454.com/products/
technologyasp. Accessed December 2014
61. Illumina (2014) Sequencing systems. http://www.illumina.com/
systems/sequencingilmn. Accessed December 2014
62. Life Technologies (2011) Ion Torrent amplicon sequencing. http://
www.3appliedbiosystems.com/cms/groups/applied_markets_
marketing/documents/generaldocuments/cms_094273.pdf.
Accessed December 2014
63. Quail MA, Smith M, Coupland P, Otto TD, Harris SR, Connor TR,
Bertoni A, Swerdlow HP, Gu Y (2012) A tale of three next gener-
ation sequencing platforms: comparison of Ion Torrent, Pacific
Biosciences and Illumina MiSeq sequencers. BMC Genomics 13:
341
64. Liu L, Li Y, Li S, Hu N, He Y, Pong R, Lin D, Lu L, LawM (2012)
Comparison of next-generation sequencing systems. J Biomed
Biotechnol 2012:251364
65. RossMG, Russ C, CostelloM,Hollinger A, LennonNJ, Hegarty R,
Nusbaum C, Jaffe DB (2013) Characterizing and measuring bias in
sequence data. Genome Biol 14:R51
66. Rothberg JM, Hinz W, Rearick TM, Schultz J, Mileski W, Davey
M, Leamon JH, Johnson K, Milgrew MJ, Edwards M, Hoon J,
Simons JF, Marran D, Myers JW, Davidson JF, et al. (2011) An
integrated semiconductor device enabling non-optical genome se-
quencing. Nature 475:348–352
67. Tops BB, Normanno N, Kurth H, Amato E, Mafficini A, Rieber N,
Le Corre D, Rachiglio AM, Reiman A, Sheils O, Noppen C,
Lacroix L, Cree IA, Scarpa A, Ligtenberg MJ, Laurent-Puig P
(2015) Development of a semi-conductor sequencing-based panel
for genotyping of colon and lung cancer by the OncoNetwork
Consortium. BMC Cancer 15:26
68. Vogelstein B, Kinzler KW (1999) Digital PCR. Proc Natl Acad Sci
U S A 96:9236–9241
69. Li M, ChenWD, Papadopoulos N, Goodman SN, Bjerregaard NC,
Laurberg S, Levin B, Juhl H, Arber N, Moinova H, Durkee K,
Schmidt K, He Y, Diehl F, Velculescu VE, et al. (2009) Sensitive
digital quantification of DNA methylation in clinical samples. Nat
Biotechnol 27:858–863
70. Hiatt JB, Pritchard CC, Salipante SJ, O’Roak BJ, Shendure J (2013)
Single molecule molecular inversion probes for targeted, high-
accuracy detection of low-frequency variation. Genome Res 23:
843–854
71. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N,
Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad
NS, Bardelli A, Brem H, Cameron JL, et al. (2014) Detection of
circulating tumor DNA in early- and late-stage human malignan-
cies. Sci Transl Med 6:224ra224
72. Dressman D, Yan H, Traverso G, Kinzler KW, Vogelstein B (2003)
Transforming single DNAmolecules into fluorescent magnetic par-
ticles for detection and enumeration of genetic variations. Proc Natl
Acad Sci U S A 100:8817–8822
73. Tejpar S, Lenz H-J, Köhne C-H, Heinemann V, Ciardiello F, Esser
R, Beier F, Stroh C, Duecker C, Bokemeyer C (2014) Effect of
KRAS and NRAS mutations on treatment outcomes in patients
with metastatic colorectal cancer (mCRC) treated first-line with
cetuximab plus FOLFOX4: new results from the OPUS study. J
Clin Oncol 32 (Suppl 3):Abstract #LBA444
74. Ciardiello F, Lenz H-J, Kohne CH, Heinemann V, Tejpar S, Esser
R, Beier F, Stroh C, Duecker C, Van Cutsem E (2014) Effect of
KRAS and NRAS mutational status on first-line treatment with
FOLFIRI plus cetuximab in patients with metastatic colorectal can-
cer (mCRC): new results from the CRYSTAL trial. J Clin Oncol 32
(Suppl 3):Abstract #LBA443
75. Azuara D, Ginesta MM, Gausachs M, Rodriguez-Moranta F,
Fabregat J, Busquets J, Pelaez N, Boadas J, Galter S, Moreno V,
Costa J, de Oca J, Capella G (2012) Nanofluidic digital PCR for
KRAS mutation detection and quantification in gastrointestinal
cancer. Clin Chem 58:1332–1341
76. Taly V, Pekin D, Benhaim L, Kotsopoulos SK, Le CD, Li X,
Atochin I, Link DR, Griffiths AD, Pallier K, Blons H, Bouche O,
Landi B, Hutchison JB, Laurent-Puig P (2013) Multiplex
picodroplet digital PCR to detect KRAS mutations in circulating
DNA from the plasma of colorectal cancer patients. Clin Chem 59:
1722–1731
77. European Commission (1998) Directive 98/79/EC of the European
Parliament and of the Council of 27 October 1998 on in vitro diag-
nostic medical devices. http://www.emergogroup.com/sites/default/
files/file/in-vitro-diagnostics-directive-98-79-ec-v2_0.pdf.
Accessed December 2014
78. Transgenomic Inc. (2013) Instructions for use for the CRC
RAScan™ Combination Kit. http://worldtransgenomic.com/files/
literature/482427-EN.pdf. Accessed December 2014
79. Transgenomic Inc. (2013) Instructions for use for the CRC
RASseq™ kit. http://worldtransgenomic.com/files/literature/
482482-EN.pdf. Accessed December 2014
80. Qiagen (2011) Therascreen KRAS Pyro Kit handbook v1.
http://tinyurl.com/lkbdk2f. Accessed December 2014
81. Qiagen (2011) Therascreen NRAS Pyro Kit handbook v1.
http://tinyurl.com/m64zerb. Accessed December 2014
82. Agena Bioscience (2014) OncoCarta™ panel v1.0. http://agenabio.
com/wp-content/uploads/2015/05/51-20010R2.0-OncoCarta-
Panel-v1.0-Flyer_WEB.pdf. Accessed July 2015
83. Sequenom (2010) A rapid and highly sensitive method for somatic
mutation profiling using the Sequenom MassARRAY® system.
http://www.biotechniques.com/protocols/A-rapid-and-highly-
sensitive-method-for-somatic-mutation-profiling—using-the-
Sequenom-MassARRAY-System/biotechniques-312575.html.
Accessed December 2014
84. Qiagen (2012) Therascreen KRAS RGQ PCR kit handbook.
http://www.accessdatafda.gov/cdrh_docs/pdf11/P110030c.pdf.
Accessed December 2014
85. Roche (2014) cobas® KRAS mutation test. http://molecularroche.
com/assays/Pages/cobasKRASMutationTestaspx. Accessed
December 2014
86. Randox (2014) KRAS/BRAF/PIK3CA array. http://www.randox.
com/kras-colorectal-molecular-test.php. Accessed December 2014
87. AutoGenomics (2014) INFINITI® KRAS. http://www.
autogenomics.com/?q=node/199. Accessed December 2014
88. Farina Sarasqueta A, Moerland E, de Bruyne H, de Graaf H,
Vrancken T, van Lijnschoten G, van den Brule AJ (2011)
SNaPshot and StripAssay as valuable alternatives to direct sequenc-
ing for KRAS mutation detection in colon cancer routine diagnos-
tics. J Mol Diagn 13:199–205
89. EnteroGen (2014) K-Ras and B-Raf mutation analysis kits.
http://www.entrogen.com/web2/k-ras-braf-mutation-test-kit.
Accessed December 2014
90. Tib Molbiol (2014) Oligonucleotides, design for PCR and
LightCycler. http://www.roche-ases/logs/LightMix%C2%AE_40-
0654-16_NRAS-KRAS_V131201a.pdf. Accessed December 2014
91. Panagene (2012) PNAClamp™ KRAS mutation detection kit (Ver.
2). http://www.pnabio.com/pdf/PNAClamp_KRAS_Manual_v12.
pdf. Accessed December 2014
92. AB Analitica (2014) REALQUALITY RI-KRAS MuST technical
leaflet. http://www.abanaliticait/download/?ID=545. Accessed
December 2014
Virchows Arch (2016) 468:383–396 395
93. Qiagen (2013) RAS extension pyro kit handbook. http://tinyurl.
com/qedz9wm. Accessed December 2014
94. Oeth P, del Mistro G, Marnellos G, Shi T, van den Boom D (2009)
Qualitative and quantitative genotyping using single base primer
extension coupled with matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry (MassARRAY). Methods Mol
Biol 578:307–343
95. Domagala P, Hybiak J, Sulzyc-Bielicka V, Cybulski C, Rys J,
Domagala W (2012) KRAS mutation testing in colorectal cancer
as an example of the pathologist’s role in personalized targeted
therapy: a practical approach. Pol J Pathol 63:145–164
96. Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C,
Kalsheker N, Smith JC, Markham AF (1989) Analysis of any point
mutation in DNA. The amplification refractory mutation system
(ARMS). Nucleic Acids Res 17:2503–2516
97. Mixich F, Ioana M, Voinea F, Saftoiu A, Ciurea T (2007)
Noninvasive detection through REMS-PCR technique of K-ras
mutations in stool DNA of patients with colorectal cancer. J
Gastrointestin Liver Dis 16:5–10
98. Amicarelli G, Shehi E, Makrigiorgos GM, Adlerstein D (2007)
FLAG assay as a novel method for real-time signal generation
during PCR: application to detection and genotyping of KRAS
codon 12 mutations. Nucleic Acids Res 35:e131
99. Kimura K, Nagasaka T, Hoshizima N, Sasamoto H, Notohara K,
Takeda M, Kominami K, Iishii T, Tanaka N, Matsubara N (2007)
No duplicate KRAS mutation is identified on the same allele in
gastric or colorectal cancer cells with multiple KRAS mutations. J
Int Med Res 35:450–457
100. Khanna M, Park P, Zirvi M, Cao W, Picon A, Day J, Paty P,
Barany F (1999) Multiplex PCR/LDR for detection of K-ras mu-
tations in primary colon tumors. Oncogene 18:27–38
101. Tsiatis AC, Norris-Kirby A, Rich RG, Hafez MJ, Gocke CD,
Eshleman JR, Murphy KM (2010) Comparison of Sanger se-
quencing, pyrosequencing, and melting curve analysis for the de-
tection of KRASmutations: diagnostic and clinical implications. J
Mol Diagn 12:425–432
102. Blons H, Rouleau E, Charrier N, Chatellier G, Cote JF, Pages JC,
de Fraipont F, Boyer JC, Merlio JP, Morel A, Gorisse MC,
de Cremoux P, Leroy K, Milano G, Ouafik L, et al. (2013)
Performance and cost efficiency of KRAS mutation testing for
metastatic colorectal cancer in routine diagnosis: the
MOKAECM study, a nationwide experience. PLoSOne 8:e68945
103. Laurent-Puig P, Pekin D, Normand C, Kotsopoulos SK, Nizard P,
Perez-Toralla K, Rowell R, Olson J, Srinivasan P, Le Corre D, Hor
T, El Harrak Z, Li X, Link DR, Bouche O, et al. (2015) Clinical
relevance of KRAS-mutated subclones detected with picodroplet
digital PCR in advanced colorectal cancer treated with anti-EGFR
therapy. Clin Cancer Res 21:1087–1097
104. van Krieken JH, Siebers AG, Normanno N (2013) European con-
sensus conference for external quality assessment in molecular
pathology. Ann Oncol 24:1958–1963
105. Bennett NC, Farah CS (2014) Next-generation sequencing in clin-
ical oncology: next steps towards clinical validation. Cancers
(Basel) 6:2296–2312
106. Weiss MM, Van der Zwaag B, Jongbloed JD, Vogel MJ,
Brüggenwirth HT, Lekanne Deprez RH, Mook O, Ruivenkamp
CA, van Slegtenhorst MA, van den Wijngaard A, Waisfisz Q,
Nelen MR, van der Stoep N (2013) Best practice guidelines for
the use of next-generation sequencing applications in genome
diagnostics: a national collaborative study of Dutch genome di-
agnostic laboratories. Hum Mutat 34:1313–1321
107. Brownstein CA, Beggs AH, Homer N, Merriman B, Yu TW,
Flannery KC, DeChene ET, Towne MC, Savage SK, Price EN,
Holm IA, Luquette LJ, Lyon E,Majzoub J, Neupert P, et al. (2014)
An international effort towards developing standards for best prac-
tices in analysis, interpretation and reporting of clinical genome
sequencing results in the CLARITY Challenge. Genome Biol 15:
R53
108. College of American Pathologists (2014) Accreditation and labo-
ratory improvement. http://www.cap.org/apps/capportal?_nfpb=
true&_pageLabel=accreditation. Accessed December 2014
109. UK NEQAS (2014) United Kingdom National External Quality
Assessment Service. http://www.ukneqas.org.uk/content/
PageServerasp?S=977247289&C=1252&CID=1&type=G.
Accessed December 2014
110. EMQN (2014) European Molecular Genetics Quality Network.
http://www.emqn.org. Accessed December 2014
111. DGKL (2014) The German Society For Clinical Chemistry And
Laboratory Medicine. http://www.dgkl.de/. Accessed December
2014
112. Normanno N, Pinto C, Castiglione F, Bardelli A, Gambacorta M,
Botti G, Nappi O, Siena S, Ciardiello F, Taddei G, Marchetti A
(2011) KRASmutations testing in colorectal carcinoma patients in
Italy: from guidelines to external quality assessment. PLoS One 6:
e29146
113. European Society of Pathology (2013) Gen&Tiss. http://
kraseqascheme.org/info/public/gen_tissx.html. Accessed
December 2014
114. Gen&Tiss (2014) Accueil. http://www.genetiss.org/. Accessed
December 2014
115. European Society of Pathology (2014) Colon external quality as-
sessment scheme. http://kraseqascheme.org/. Accessed December
2014
116. Cree IA, Deans Z, Ligtenberg MJ, Normanno N, Edsjo A,
Rouleau E, Sole F, Thunnissen E, Timens W, Schuuring E,
Dequeker E, Murray S, Dietel M, Groenen P, van Krieken JH
(2014) Guidance for laboratories performing molecular pathology
for cancer patients. J Clin Pathol 67:923–931
117. OECD (2014) Guidel ines for qual i ty assurance in
gene t i c t e s t i ng . h t t p : / /www.oecdo rg / s t i / b i o t e ch /
oecdguidelinesforqualityassuranceingenetictesting.htm.
Accessed December 2014
118. van Krieken JH, Normanno N, Blackhall F, Boone E, Botti G,
Carneiro F, Celik I, Ciardiello F, Cree IA, Deans ZC, Edsjo A,
Groenen PJ, Kamarainen O, Kreipe HH, Ligtenberg MJ, et al.
(2013) Guideline on the requirements of external quality assess-
ment programs inmolecular pathology. Virchows Arch 462:27–37
119. OECD (1998) Principles on good laboratory practice. http://
searchoecd.org/officialdocuments/displaydocumentpdf/?cote=
env/mc/chem%2898%2917&doclanguage=en. Accessed
December 2014
120. Dubbink HJ, Deans ZC, Tops BB, van Kemenade FJ, Koljenovic
S, van Krieken HJ, Blokx WA, Dinjens WN, Groenen PJ (2014)
Next generation diagnostic molecular pathology: critical appraisal
of quality assurance in Europe. Mol Oncol 8:830–839
121. Berwouts S, Morris MA, Dequeker E (2010) Approaches to qual-
ity management and accreditation in a genetic testing laboratory.
Eur J Hum Genet 18(Suppl 1):S1–19
122. Mattocks CJ, Morris MA, Matthijs G, Swinnen E, Corveleyn A,
Dequeker E, Muller CR, Pratt V,Wallace A (2010) A standardized
framework for the validation and verification of clinical molecular
genetic tests. Eur J Hum Genet 18:1276–1288
123. Deans ZC, Bilbe N, O’Sullivan B, Lazarou LP, de Castro DG,
Parry S, Dodson A, Taniere P, Clark C, Butler R (2013)
Improvement in the quality of molecular analysis of EGFR in
non-small-cell lung cancer detected by three rounds of external
quality assessment. J Clin Pathol 66:319–325
396 Virchows Arch (2016) 468:383–396
